Advances in Local and Systemic Therapies for Hepatocellular Cancer

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Global incidence and mortality of hepatocellular carcinoma (HCC) has increased over the past two decades. Although transplantation and surgical resection offer a chance for cure and long-term survival, most patients present with more advanced tumor stage when these therapies are not possible. Although rarely curative, locoregional therapy with transarterial chemoembolization or radioembolization offers a survival benefit for those with liver-isolated HCC who are not amenable to curative therapies. Patients with metastatic disease or macrovascular invasion are treated with systemic therapy; however, median survival remains below 1 year. Patients with severe liver dysfunction or poor performance status should be treated with best supportive care given poor prognosis and no survival benefit for treatment. Lack of predictive and prognostic biomarkers in intermediate and advanced HCC tumors has hampered integration of clinical and molecular data to aid tailoring treatment decisions. However, with increasingly complex treatment decisions, optimal outcomes are achieved through multidisciplinary care.

Original languageEnglish (US)
Article number9
Pages (from-to)1-12
Number of pages12
JournalCurrent oncology reports
Issue number2
StatePublished - Feb 1 2016


  • Hepatocellular carcinoma
  • Liver cancer
  • Liver disease
  • Locoregional therapy
  • Staging
  • Systemic therapy

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Advances in Local and Systemic Therapies for Hepatocellular Cancer'. Together they form a unique fingerprint.

Cite this